Delivery Order SPE2DB25D3404-SPE2DB25FUMYC

Award Date 4/14/25
Potential Completion Date 5/5/25
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 mg/10 ml vials over a performance period ending on May 20, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58 and a period of performance through March 4, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $34,955.36 and runs through April 2, 2025. The contract is a firm fixed-price, delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, at a firm fixed price. The contract has a ceiling value of $120,192.80 and a completion date of May 20, 2025. This award is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has a ceiling value of $54,395.32 and a completion date of October 10, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a medication, with a ceiling value of $60,096.40 and a period of performance through May 19, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract has a firm fixed price of $120,192.80 and a period of performance through June 4, 2025. This contract is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,038.58, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract is a firm fixed-price delivery order, with a period of performance through May 9, 2025. This contract is not designated as a set-aside and was open to full and open competition....
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $36,057.84, is for the provision of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price delivery order that is not designated with any set-aside requirements, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, with a ceiling value of $120,192.80. The contract is a Firm Fixed Price Delivery Order that runs through April 14, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) the company holds with the DLA Troop Support...
  • SPE2DB25D3404
    Indefinite Delivery Contract
  • SPE2DB25D3404-SPE2DB25FUMYC
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58 and runs through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 7/14/25, 11:08 AM